NICE Backed Acalabrutinib and Venetoclax Without Obinutuzumab, and the Omission Is the Decision
- NICE recommended acalabrutinib in two first-line combinations on 6 August 2026: with bendamustine and rituximab for untreated mantle cell lymphoma, and with venetoclax for untreated chronic lymphocytic leukaemia.
- In MCL, adding acalabrutinib to bendamustine and rituximab extended the time before the condition worsened to 72.5 months against 47.8 months for standard treatment alone, a gap of nearly 25 months in a disease NICE describes as incurable and prone to return.
- In CLL the recommendation is specifically for acalabrutinib with venetoclax without obinutuzumab, with around 440 people expected to benefit. Evidence came from the AMPLIFY trial, which showed improved progression-free and overall survival against standard chemoimmunotherapy.
- NICE emphasises that the CLL combination is taken as a daily pill rather than by intravenous infusion, meaning fewer hospital trips, and that clinical experts considered it generally well tolerated and therefore suitable for a broader range of people, including older fitter patients.
Two recommendations, one molecule
| Mantle cell lymphoma | Chronic lymphocytic leukaemia | |
|---|---|---|
| Regimen | Acalabrutinib with bendamustine and rituximab | Acalabrutinib with venetoclax, no obinutuzumab |
| Population | Untreated | Untreated |
| Evidence | Time to worsening 72.5 vs 47.8 months | PFS and OS improved vs chemoimmunotherapy (AMPLIFY) |
| Delivery | Oral plus intravenous | All oral, daily pill |
| Set to benefit | Not separately stated | Around 440 |
Figures as published by NICE. The MCL comparator is bendamustine and rituximab alone. NICE describes the combined MCL and CLL cohorts only as hundreds of people.
Access read
Two words carry this appraisal, and they are without obinutuzumab. AMPLIFY studied acalabrutinib and venetoclax both with and without the anti-CD20 antibody, and NICE recommended the doublet. Choosing between two arms of the same trial is not a clinical footnote, it is a committee selecting a cost and a delivery model in the same movement. The triplet would have added a third acquisition cost and an infused antibody, and the committee did not judge that worth funding.
- The oral route is doing value-case work that efficacy cannot. NICE says it plainly: a daily pill rather than an intravenous infusion, fewer hospital trips, easier to fit around work and family. In a health service where infusion capacity is among the scarcest resources in oncology, an all-oral regimen releases chair time, nursing hours and day-unit slots that never surface in a cost-per-QALY calculation but appear immediately in a trust’s operational plan. Read the obinutuzumab omission through that lens and it is consistent. NICE did not only decline a third drug, it declined the infusion that arrives attached to it.
- The mantle cell number deserves stating without decoration. Time to worsening of 72.5 months against 47.8 is close to two additional years before the second-line conversation has to happen, in first line, in a disease NICE calls incurable. Where many patients are never well enough for a stem cell transplant, first-line durability is close to the only lever available, which is why the committee’s patient expert framed access to the best first option as essential rather than preferable. That framing is what carries an appraisal, and it is worth noting NICE chose to publish it.
- What to watch: whether the final guidance carries a commercial arrangement, because a NICE yes conditioned on a confidential discount tells you the list price was not the price, and that clause is where the economics actually sit. Then watch what the omission does to obinutuzumab in first-line CLL in England, now that a national assessment body has recommended the regimen that leaves it out. And note the status, since this is final draft guidance rather than published guidance, so consultee comment is still open and the wording can move.